What the FDA labels say about taking them together
Atovaquone and rifabutin
Atovaquone's FDA label of March 20, 2026 names rifabutin in its drug interactions section; the rifabutin label PlainMeds reads does not name atovaquone. The atovaquone label: “Concomitant administration of rifampin or rifabutin reduces atovaquone concentrations; concomitant use with MEPRON oral suspension is not recommended.”
Check it at the source: the atovaquone FDA label on DailyMed (effective March 20, 2026); the rifabutin FDA label on DailyMed (effective September 1, 2026, REMEDYREPACK INC.).
What does the atovaquone label say about rifabutin?
Atovaquone label, drug interactionsConcomitant administration of rifampin or rifabutin reduces atovaquone concentrations; concomitant use with MEPRON oral suspension is not recommended.
Source: FDA drug label (MEPRON), GlaxoSmithKline LLC, effective March 20, 2026 (SPL set b426b6bf-f07e-4580-97ae-dfca1ddf5b8f), via openFDA; the full label on DailyMed
What does the rifabutin label say about atovaquone?
Rifabutin's label (effective September 1, 2026) does not name atovaquone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Rifabutin), NDA050689 (Pfizer), as published by REMEDYREPACK INC., effective September 1, 2026 (SPL set 25a60937-cbbe-4a50-994f-2ce15203f589), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atovaquone | Rifabutin | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.767 per mL 750 mg/5 mL suspension | $8.14 per capsule 150 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once